Search Results
33 items found for "Treatment"
- Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease
Committee Sponsors GPCR Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment
- Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis
< GPCR News < GPCRs in Oncology and Immunology Exploration of prognostic and treatment markers in hepatocellular elucidated, and GPCR-related genes were employed for building a risk-score model for the prognosis and treatment prediction model was constructed by only GPCR-related genes, which are all potential targets for HCC treatment Baoluhe Zhang , Xiaokun Chen , Xiao Liu , Xueshuai Wan , Shunda Du Tags GPCR ; HCC ; Prognosis ; Systemic treatment
- Elucidation of active components and target mechanism in Jinqiancao granules for the treatment of prostatitis and benign prostatic hyperplasia
and Immunology Elucidation of active components and target mechanism in Jinqiancao granules for the treatment to elucidate active compounds in Jinqiancao granules and their target mechanisms for the potential treatment The findings provide scientific evidence for the potential use of Jinqiancao granules as a treatment
- Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
Despite advances in the treatment, many patients experience disease relapse or become refractory to treatment Talquetamab, a Food and Drug Administration-approved T-cell-directing bispecific antibody developed for treatment
- NPFF stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling
Treatment of SKOV3 cells with NPFF did not affect cell viability and proliferation but stimulated cell NPFF treatment upregulates matrix metalloproteinase-9 (MMP-9) expression. Our results also showed that ERK1/2 signaling was activated in SKOV3 cells in response to the NPFF treatment
- G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression
Finally, we review the progress of clinical trials of GPCR-targeted drugs for cancer treatment, which may be combined with immunotherapy to improve treatment efficacy.
- Ep 121 with Yao Lu (Jackie)
investigating the role of functional selectivity in a novel class of potential antipsychotics for the treatment
- The Effect of Cancer-Associated Mutations on Ligand Binding and Receptor Function - A Case for the 5-HT2C Receptor
mood, appetite, and reproductive behavior, it has been identified as a potential target for cancer treatment Such mutations may affect serotonin-mediated signaling in tumor cells as well as treatment strategies
- Comparative Analysis of the GNAI Family Genes in Glioblastoma through Transcriptomics and Single-Cell Technologies
The treatment of GBM is challenging due to the presence of the blood-brain barrier (BBB), which hinders Hence, identifying the crucial pathways and biomarkers for the treatment of GBM is of prime importance
- Drosophila cytokine GBP2 exerts immune responses and regulates GBP1 expression through GPCR receptor Mthl10
Moreover, the GBP2-induced response was silenced by pre-treatment with dsRNA targeting the GBP receptor Furthermore, treatment of S2 cells with GBP2 enhanced GBP1 expression levels, but GBP1 did not affect
- Clinical, pathophysiologic, genetic and therapeutic progress in Primary Bilateral Macronodular Adrenal Hyperplasia
Treatment is reserved for patients with overt or mild cortisol/aldosterone or other steroid excesses adrenalectomy; however recent studies tend to favor unilateral adrenalectomy, or less frequently, medical treatment
- Ep 82 with Dr. Lauren M. Slosky
multidisciplinary initiative within the University of Minnesota’s Medical School to advance research and treatment receptor allosterism and functional selectivity can be leveraged in the development of safe and effective treatments
- Ep 79 with Dr. Graeme Milligan
steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments
- Ep 64 with Dylan Eiger
He hopes to continue his research on biased agonism at GPCRs with a particular focus on the treatment
- G Proteins and GPCRs in Cancer: Novel Precision Targeted and Immunotherapies
signaling circuitries and individual genomic and molecular alterations to develop new precision cancer treatments
- Ep 107 with Dr. Roger Sunahara
Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy The laboratory continues to engineer the enzyme to optimize its potential as a treatment for cocaine
- Olfactory Receptors and Tumorigenesis: Implications for Diagnosis and Targeted Therapy
and targeted therapy through therapeutic targeting of olfactory receptors as an adjunct anticancer treatment
- Ep 45 with Dr Ralf Jockers
variants are biased and their defects are signaling pathway-specific opening new perspectives for T2D treatment
- Atypical Structure and Function of Typical Chemokine Receptors
of biochemical and behavioural approaches to understand the many roles of NMDA receptors and to find treatments
- Trainee Symposium I
studies, Emile is interested in characterizing novel G protein-coupled receptors (GPCRs) ligands for the treatment
- Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer
Taken together, current data are prompting the hypothesis of a prophylactic treatment option with stable
- Ep 113 with Dr. Prasenjit Saha
receptors and serve as targets for more than one-third of all prescribed drugs currently used in the treatment
- The EBI2 receptor is coexpressed with CCR5 in CD4+ T cells and boosts HIV-1 R5 replication
the effect of EBI2 antagonists on the residual viral production persisting in patients aviremic under treatment
- Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design
involvement of PAR PH binding motif signaling in ovarian cancer and Pc(4-4) as a potential therapy treatment
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Sabbagh led research projects aimed on drug discovery of small molecules for the treatment of inflammatory knowledge to identify novel pharmacological targets and contribute to the development of innovative treatments
- GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis
The possible biological mechanisms of GPR37 provide novel insights into the clinical diagnosis and treatment
- Session IV | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Neuroscience at Baylor College of Medicine, where he studies BAI1's role in the brain and the radiobiology of treatments
- Ep 146 with Dr Michael Feigin
Yamina proposed further exploration of dosage and length of treatment in a mouse model and suggested highlighted the complexities and challenges of drug prescription and the potential for alternative treatments